Several FGFR inhibitors have been tested in pediatric and adult patients with glioma, including erdafitinib (58) and the FGFR1–3 inhibitor infigratinib (59), which was investigated in a multicenter phase II study in patients with recurrent gliomas and FGFR alterations. Here, FGFR1 is linked to glioma.